URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


2nd Ligase Targeting Drug Development Summit


Date
Apr 26, 2022 - 09:00 AM - Apr 28, 06:00 PM
Organizer
Hanson Wade
Venue
Hilton Boston Logan Airport
Location
One Hotel Drive,

Boston,
MA,
US,
ZIP: 02128
Phone: +44 020 3141 8700

Ticket Price: USD 2599.00 - USD 5846.00


The 2nd Ligase Targeting Drug Development Summit returns with new insight and data from pioneers in the field to delve deep into ligase biology, assays to investigate functions as well as screening tools for optimum ligand identification and validation.

This forum will provide an unrivalled meeting-point for industry leaders, in order to strategically accelerate and de-risk the process of identifying, validating and therapeutically leveraging cell and tissue specific Ubiquitin E3 ligases for degradation or modulation of targets of interest.

Tickets    https://go.evvnt.com/965940-2?pid=1052
Brochure https://go.evvnt.com/965940-3?pid=1052

Prices:
Conference + Workshop Day or Focus Day (Drug Developer Pricing) USD 4796.00,
Conference Only (Drug Developer Pricing) USD 2999.00,
Conference + Workshop Day or Focus Day (Standard Rate) USD 5846.00,
Conference Only (Standard Rate) USD 3599.00,
Conference + Workshop Day or Focus Day (Academic Pricing) USD 4246.00,
Conference Only (Academic Pricing) USD 2599.00

Category: Conferences | Science, Health & Medicine


Speaker Details


Ellen Vieux, Senior Research Scientist, C4 Therapeutics, Jennifer Johnston, Chief Executive Officer, NysnoBio, Katie Digianantonio, Senior Research Scientist, Arvinas, Sandra Kumper, Investigator, GSK, Dan Robbins, Associate Director, Medicinal Chemistry, Nurix Therapeutics, Jennifer Venable, Senior Scientific Director, The Janssen Pharmaceutical Companies of Johnson & Johnson, Radosław Nowak, Senior Scientist, Cancer Biology, Dana-Farber Cancer Institute, Sharon Shechter, Director of Platform Integration, Roivant Sciences, Hakryul Jo, Associate Director, Platform Biology, Kymera Therapeutics, Jeff McKenna, Associate Director, Novartis institutes for Biomedical Research, Ryan Potts, Head of Induced Proximity Platform, Amgen, Satpal Virdee, MRC Investigator & Professor of Chemical Biology, MRC Protein Phosphorylation & Ubiquitylation Unit, University of Dundee, Benjamin Ruprecht, Director of Translational Proteomics, Roivant Sciences, Kevin Moreau, Associate Director, Safety Innovation & PROTAC Science Lead, AstraZeneca, Matthieu Schapira, Principal Investigator, Structural Genomics Consortium, University of Toronto, Smaranda Bodea, Associate Principal Scientist, Chemical Biology, Merck Research Laboratories, Gary Kleiger, Associate Professor, University of Nevada, Las Vegas, George Burslem, Assistant Professor, University of Pennsylvania, Richard Huang, Senior Principal Scientist & Group Leader, Bristol-Myers Squibb, Wei Zhang, Assistant Professor, University of Guelph, Corey Strickland, Vice President Molecular Technology, Proteovant, Luca Busino, Assistant Professor in Cancer Biology, University of Pennsylvania, Sarath Ramachandran, Postdoctoral Scientist, University of Dundee, Wu Du, Senior Vice President, Hinova Pharmaceuticals, Michael Rape, Investigator, HHMI; Professor; Dr. K. Peter Hirth Chair of Cancer Biology, HHMI/UC Berkeley, Qianhe Zhou, Principal Scientist, Foghorn Therapeutics

Event Categories




Comments








Events Calendar

SunMonTueWedThuFriSat
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99